Edible ginger-derived nanoparticles: A novel therapeutic approach for the prevention and treatment of inflammatory bowel disease and colitis-associated cancer.
There is a clinical need for new, more effective treatments for chronic and debilitating inflammatory bowel disease (IBD), including Crohn's disease and ulcerative colitis. In this study, we characterized a specific population of nanoparticles derived from edible ginger (GDNPs 2) and demonstrated their efficient colon targeting following oral administration. GDNPs 2 had an average size of ∼230 nm and exhibited a negative zeta potential. These nanoparticles contained high levels of lipids, a few proteins, ∼125 microRNAs (miRNAs), and large amounts of ginger bioactive constituents (6-gingerol and 6-shogaol). We also demonstrated that GDNPs 2 were mainly taken up by intestinal epithelial cells (IECs) and macrophages, and were nontoxic. Using different mouse colitis models, we showed that GDNPs 2 reduced acute colitis, enhanced intestinal repair, and prevented chronic colitis and colitis-associated cancer (CAC). 2D-DIGE/MS analyses further identified molecular target candidates of GDNPs 2 involved in these mouse models. Oral administration of GDNPs 2 increased the survival and proliferation of IECs and reduced the pro-inflammatory cytokines (TNF-α, IL-6 and IL-1β), and increased the anti-inflammatory cytokines (IL-10 and IL-22) in colitis models, suggesting that GDNPs 2 has the potential to attenuate damaging factors while promoting the healing effect. In conclusion, GDNPs 2, nanoparticles derived from edible ginger, represent a novel, natural delivery mechanism for improving IBD prevention and treatment with an added benefit of overcoming limitations such as potential toxicity and limited production scale that are common with synthetic nanoparticles.
['Zhang|Mingzhen|M|', 'Viennois|Emilie|E|', 'Prasad|Meena|M|', 'Zhang|Yunchen|Y|', 'Wang|Lixin|L|', 'Zhang|Zhan|Z|', 'Han|Moon Kwon|MK|', 'Xiao|Bo|B|', 'Xu|Changlong|C|', 'Srinivasan|Shanthi|S|', 'Merlin|Didier|D|']
D000818:Animals D000972:Antineoplastic Agents, Phytogenic D002396:Catechols D002460:Cell Line D045744:Cell Line, Tumor D003093:Colitis, Ulcerative D003110:Colonic Neoplasms D005233:Fatty Alcohols D005260:Female D020939:Ginger D006801:Humans D015212:Inflammatory Bowel Diseases D051379:Mice D008810:Mice, Inbred C57BL D053758:Nanoparticles D008517:Phytotherapy
Inflammatory bowel disease Colitis-associated cancer Edible ginger derived nanoparticles Natural drug delivery system Therapy